Eli Lilly and Company (NYSE:LLY) Shares Sold by Coastline Trust Co

Coastline Trust Co lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,871 shares of the company’s stock after selling 1,981 shares during the quarter. Eli Lilly and Company makes up about 2.0% of Coastline Trust Co’s investment portfolio, making the stock its 11th biggest position. Coastline Trust Co’s holdings in Eli Lilly and Company were worth $16,719,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. First Long Island Investors LLC grew its position in shares of Eli Lilly and Company by 1.8% in the 3rd quarter. First Long Island Investors LLC now owns 19,130 shares of the company’s stock worth $16,948,000 after acquiring an additional 346 shares in the last quarter. Simplify Asset Management Inc. raised its position in shares of Eli Lilly and Company by 67.2% during the 3rd quarter. Simplify Asset Management Inc. now owns 19,082 shares of the company’s stock worth $16,906,000 after buying an additional 7,670 shares in the last quarter. Altrius Capital Management Inc lifted its stake in shares of Eli Lilly and Company by 1.0% in the 3rd quarter. Altrius Capital Management Inc now owns 1,285 shares of the company’s stock worth $1,138,000 after acquiring an additional 13 shares during the period. KCM Investment Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 1.0% in the third quarter. KCM Investment Advisors LLC now owns 38,668 shares of the company’s stock valued at $34,258,000 after acquiring an additional 394 shares in the last quarter. Finally, Valley Wealth Managers Inc. increased its stake in shares of Eli Lilly and Company by 26.4% during the third quarter. Valley Wealth Managers Inc. now owns 2,260 shares of the company’s stock valued at $2,002,000 after acquiring an additional 472 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on LLY. Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price on the stock. Truist Financial upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Berenberg Bank lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Finally, BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 5.0 %

NYSE:LLY opened at $745.89 on Friday. The business’s fifty day moving average price is $882.65 and its 200 day moving average price is $869.77. The firm has a market capitalization of $708.09 billion, a price-to-earnings ratio of 80.64, a PEG ratio of 3.07 and a beta of 0.43. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 1-year low of $561.65 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company’s revenue was up 20.4% compared to the same quarter last year. During the same period last year, the firm earned $0.10 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.70%. Eli Lilly and Company’s payout ratio is 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.